Placebo matching vicadrostat

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Chronic Kidney DiseaseDiabetes Mellitus, Type 2

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

1

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

162

Placebo matching vicadrostat

Boehringer Ingelheim

Phase 3

13

Sovaldi

Gilead

Preclinical

14

Activase

Roche

Preclinical

—5

Epoetin Beta

Roche

Preclinical

56

PROCRIT

WWim Janssens

Preclinical

17

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

18

Singulair

OOrganon and Co

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—10

Chronulac

SSolvay Pharmaceuticals

Preclinical

—Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 21 trial

EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease

Recruiting·Boehringer Ingelheim·Phase 3·NCT07064473·11,800 enrolled

Chronic Kidney Disease1 trial

A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression

Active, not recruiting·Boehringer Ingelheim·Phase 2·NCT06926660·492 enrolled

Unspecified1 trial

Thorough QT Study to Evaluate the Effects of Single Doses of Vicadrostat on Cardiac Safety Parameters in Healthy Male and Female Subjects (a Randomized, Placebo-controlled, Double-blind, Five-period Crossover Study With Open-label Moxifloxacin as Positive Control)

Active, not recruiting·Boehringer Ingelheim·Phase 1·NCT07513207·45 enrolled

Details

Drug Info

Related News